Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and acceptance of two oral compounded hydrocortisone formulations in pediatric patients
2021-001069-20Phase 4Active
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydrocortisone in congenital adrenal hyperplasia (CAH), Addison's disease, Adrenocorticotropic hormone and 2 more (2 arms), sponsored by Vall d'Hebron University Hospital. Primary endpoints: Sensory acceptability of hydrocortisone formulations and Preferred chewable formulation presentation. Started Aug 2021; status: active.
02
Drugs
hydrocortisone
03
Conditions
congenital adrenal hyperplasia (CAH)Addison's diseaseAdrenocorticotropic hormonetertiary adrenal insufficiency (TAI)panhypopituitarism
Beyond the preview
Go deeper on 2021-001069-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001069-20.